- Home
- Publications
- Publication Search
- Publication Details
Title
COVID-19 therapeutics: Challenges and directions for the future
Authors
Keywords
-
Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 119, Issue 15, Pages -
Publisher
Proceedings of the National Academy of Sciences
Online
2022-04-07
DOI
10.1073/pnas.2119893119
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Realizing the Potential of Anti–SARS-CoV-2 Monoclonal Antibodies for COVID-19 Management
- (2022) Jonathan Z. Li et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts
- (2021) Angel YS Wong et al. ANNALS OF THE RHEUMATIC DISEASES
- Surviving COVID-19 in Bergamo Province: a post-acute outpatient re-evaluation
- (2021) S. Venturelli et al. EPIDEMIOLOGY AND INFECTION
- Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19
- (2021) Robert L. Gottlieb et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study
- (2021) Chaolin Huang et al. LANCET
- Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry
- (2021) Anja Strangfeld et al. ANNALS OF THE RHEUMATIC DISEASES
- Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
- (2021) Christopher C Butler et al. LANCET
- Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19
- (2021) NEW ENGLAND JOURNAL OF MEDICINE
- Sequelae in Adults at 6 Months After COVID-19 Infection
- (2021) Jennifer K. Logue et al. JAMA Network Open
- Genetic conservation of SARS-CoV-2 RNA replication complex in globally circulating isolates and recently emerged variants from humans and minks suggests minimal pre-existing resistance to remdesivir
- (2021) Ross Martin et al. ANTIVIRAL RESEARCH
- Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease.
- (2021) Laura Bergamaschi et al. IMMUNITY
- Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care Workers
- (2021) Sebastian Havervall et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
- (2021) Obbina Abani et al. LANCET
- Report of the Independent Panel for Pandemic Preparedness and Response: making COVID-19 the last pandemic
- (2021) Ellen Johnson Sirleaf et al. LANCET
- Diverse Functional Autoantibodies in Patients with COVID-19
- (2021) Eric Y. Wang et al. NATURE
- High-dimensional characterization of post-acute sequelae of COVID-19
- (2021) Ziyad Al-Aly et al. NATURE
- Single-cell multi-omics analysis of the immune response in COVID-19
- (2021) Emily Stephenson et al. NATURE MEDICINE
- Delayed production of neutralizing antibodies correlates with fatal COVID-19
- (2021) Carolina Lucas et al. NATURE MEDICINE
- Long COVID’s long R&D agenda
- (2021) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- Inhibitors of Protein Glycosylation Are Active against the Coronavirus Severe Acute Respiratory Syndrome Coronavirus SARS-CoV-2
- (2021) Sreejith Rajasekharan et al. Viruses-Basel
- Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial
- (2021) Sanjay Ramakrishnan et al. Lancet Respiratory Medicine
- Phase-Adapted Rehabilitation for Acute Coronavirus Disease-19 Patients and Patient With Long-term Sequelae of Coronavirus Disease-19
- (2021) Christoph Gutenbrunner et al. AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION
- Symptoms After COVID-19 Vaccination in Patients With Persistent Symptoms After Acute Infection: A Case Series
- (2021) David T. Arnold et al. ANNALS OF INTERNAL MEDICINE
- Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2
- (2021) Parakkal Deepak et al. ANNALS OF INTERNAL MEDICINE
- Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study
- (2021) Victoria Furer et al. ANNALS OF THE RHEUMATIC DISEASES
- Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit
- (2021) Matthew D Hall et al. JOURNAL OF INFECTIOUS DISEASES
- Evolution of viral variants in remdesivir‐treated and untreated SARS‐CoV‐2‐infected pediatrics patients
- (2021) Florencia A. T. Boshier et al. JOURNAL OF MEDICAL VIROLOGY
- Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
- (2021) Ly-Mee Yu et al. LANCET
- Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial
- (2021) Renato D Lopes et al. LANCET
- Dysregulation of brain and choroid plexus cell types in severe COVID-19
- (2021) Andrew C. Yang et al. NATURE
- Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19
- (2021) Michael Dougan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia
- (2021) Patrícia O. Guimarães et al. NEW ENGLAND JOURNAL OF MEDICINE
- Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19
- (2021) NEW ENGLAND JOURNAL OF MEDICINE
- Early antibody responses associated with survival in COVID19 patients
- (2021) Zhao-Hua Zhou et al. PLoS Pathogens
- Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial
- (2021) Jean-Claude Tardif et al. Lancet Respiratory Medicine
- Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients
- (2021) Angélica Jayk Bernal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab
- (2021) Anil Gupta et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hyperpolarized 129Xe MRI Abnormalities in Dyspneic Patients 3 Months after COVID-19 Pneumonia: Preliminary Results
- (2021) James T. Grist et al. RADIOLOGY
- Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial
- (2021) Benjamin A Fisher et al. Lancet Respiratory Medicine
- Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19
- (2021) Zara Izadi et al. JAMA Network Open
- Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury
- (2020) Clark D Russell et al. LANCET
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
- (2020) Chaolin Huang et al. LANCET
- Autopsy Findings and Venous Thromboembolism in Patients With COVID-19
- (2020) Dominic Wichmann et al. ANNALS OF INTERNAL MEDICINE
- Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19
- (2020) Maximilian F Konig et al. ANNALS OF THE RHEUMATIC DISEASES
- Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry
- (2020) Milena Gianfrancesco et al. ANNALS OF THE RHEUMATIC DISEASES
- Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China
- (2020) Chuan Qin et al. CLINICAL INFECTIOUS DISEASES
- Corticosteroids, but not TNF Antagonists, are Associated with Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results from an International Registry
- (2020) Erica J. Brenner et al. GASTROENTEROLOGY
- High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study
- (2020) Julie Helms et al. INTENSIVE CARE MEDICINE
- Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19
- (2020) Yang Yang et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Targeting Endoplasmic Reticulum α-Glucosidase I with a Single-Dose Iminosugar Treatment Protects against Lethal Influenza and Dengue Virus Infections
- (2020) Kelly L. Warfield et al. JOURNAL OF MEDICINAL CHEMISTRY
- High incidence of venous thromboembolic events in anticoagulated severe COVID‐19 patients
- (2020) Jean‐François Llitjos et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed
- (2020) Marc Feldmann et al. LANCET
- Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19
- (2020) Maximilian Ackermann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Remdesivir for the Treatment of Covid-19 — Preliminary Report
- (2020) John H. Beigel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effective treatment of severe COVID-19 patients with tocilizumab
- (2020) Xiaoling Xu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans
- (2020) Sharon E Fox et al. Lancet Respiratory Medicine
- α-glucosidase inhibitors as host-directed antiviral agents with potential for the treatment of COVID-19
- (2020) Spencer J. Williams et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- Immunothrombotic Dysregulation in COVID-19 Pneumonia is Associated with Respiratory Failure and Coagulopathy
- (2020) Leo Nicolai et al. CIRCULATION
- Low ADAMTS 13 plasma levels are predictors of mortality in COVID-19 patients
- (2020) Mario Bazzan et al. Internal and Emergency Medicine
- Factors associated with COVID-19-related death using OpenSAFELY
- (2020) Elizabeth J. Williamson et al. NATURE
- Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report
- (2020) NEW ENGLAND JOURNAL OF MEDICINE
- Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications
- (2020) Divij Mathew et al. SCIENCE
- Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study
- (2020) George Goshua et al. Lancet Haematology
- Levels of the TNF-Related Cytokine LIGHT Increase in Hospitalized COVID-19 Patients with Cytokine Release Syndrome and ARDS
- (2020) David S. Perlin et al. mSphere
- The looming storm: Blood and cytokines in COVID-19
- (2020) Supreet Kaur et al. BLOOD REVIEWS
- Remdesivir failure with SARS-CoV-2 RNA-dependent RNA-polymerase mutation in a B-cell immunodeficient patient with protracted Covid-19
- (2020) Martin Martinot et al. CLINICAL INFECTIOUS DISEASES
- Effect of IBD medications on COVID-19 outcomes: results from an international registry
- (2020) Ryan C Ungaro et al. GUT
- Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19
- (2020) Bruno M. Tomazini et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19
- (2020) et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19
- (2020) et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon
- (2020) Lydia J. Finney et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Complement and tissue factor–enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis
- (2020) Panagiotis Skendros et al. JOURNAL OF CLINICAL INVESTIGATION
- An inflammatory cytokine signature predicts COVID-19 severity and survival
- (2020) Diane Marie Del Valle et al. NATURE MEDICINE
- A dynamic COVID-19 immune signature includes associations with poor prognosis
- (2020) Adam G. Laing et al. NATURE MEDICINE
- Reduced development of COVID-19 in children reveals molecular checkpoints gating pathogenesis illuminating potential therapeutics
- (2020) Jonathan Baruch Steinman et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Inborn errors of type I IFN immunity in patients with life-threatening COVID-19
- (2020) Qian Zhang et al. SCIENCE
- Autoantibodies against type I IFNs in patients with life-threatening COVID-19
- (2020) Paul Bastard et al. SCIENCE
- Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform
- (2020) Anna Schultze et al. Lancet Respiratory Medicine
- Human recombinant soluble ACE2 in severe COVID-19
- (2020) Alexander Zoufaly et al. Lancet Respiratory Medicine
- Longitudinal immune profiling reveals key myeloid signatures associated with COVID-19
- (2020) Elizabeth R. Mann et al. Science Immunology
- Antifibrotics in COVID-19 Lung Disease: Let Us Stay Focused
- (2020) Sachin Chaudhary et al. Frontiers in Medicine
- Human soluble ACE2 improves the effect of remdesivir in SARS‐CoV‐2 infection
- (2020) Vanessa Monteil et al. EMBO Molecular Medicine
- Longitudinal Multi-omics Analyses Identify Responses of Megakaryocytes, Erythroid Cells, and Plasmablasts as Hallmarks of Severe COVID-19
- (2020) Joana P. Bernardes et al. IMMUNITY
- Vascular neutrophilic inflammation and immunothrombosis distinguish severe COVID‐19 from influenza pneumonia
- (2020) Leo Nicolai et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results
- (2020) NEW ENGLAND JOURNAL OF MEDICINE
- REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
- (2020) David M. Weinreich et al. NEW ENGLAND JOURNAL OF MEDICINE
- Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
- (2020) Andre C. Kalil et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19
- (2020) NEW ENGLAND JOURNAL OF MEDICINE
- SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
- (2020) Peter Chen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Increased interleukin-6 and macrophage chemoattractant protein-1 are associated with respiratory failure in COVID-19
- (2020) Marthe Jøntvedt Jørgensen et al. Scientific Reports
- Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial
- (2020) Phillip D Monk et al. Lancet Respiratory Medicine
- JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
- (2017) Daniella M. Schwartz et al. NATURE REVIEWS DRUG DISCOVERY
- Embracing proteins: structural themes in aptamer–protein complexes
- (2016) Amy D Gelinas et al. CURRENT OPINION IN STRUCTURAL BIOLOGY
- Carboxyfullerene neuroprotection postinjury in Parkinsonian nonhuman primates
- (2014) Laura L. Dugan et al. ANNALS OF NEUROLOGY
- Nucleic Acid Ligands With Protein-like Side Chains: Modified Aptamers and Their Use as Diagnostic and Therapeutic Agents
- (2014) John C Rohloff et al. Molecular Therapy-Nucleic Acids
- Aptamer-Based Multiplexed Proteomic Technology for Biomarker Discovery
- (2011) Larry Gold et al. PLoS One
- Safety of Inhaled Budesonide
- (2008) Camilla Christensson et al. DRUG SAFETY
- Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets
- (2008) May H. Han et al. NATURE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started